At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 103 enrolled
Drug / intervention
sitagliptin phosphate +2 moredrug
Likely dose
sitagliptin phosphate 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1b, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Crossover Clinical Trial of Sitagliptin 100 mg and Sitagliptin 200 mg in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet and Exercise
In Brief
A Phase 1 clinical trial evaluating sitagliptin phosphate and Comparator: Placebo for Type 2 Diabetes. Completed, enrolled 103 participants.
Detailed Summary
A study to assess the safety and efficacy of sitagliptin 100mg compared to sitagliptin 200mg in patients with type 2 diabetes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
Countries--
Collaborators--
Timeline
Phase 1CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2007
First PostedOct 2007
Primary CompletionJun 2008
Study CompletionJul 2008
TodayJul 2026
First PostedOct 10, 2007
Enrollment StartAug 24, 2007
Primary CompletionJun 17, 2008
Study CompletionJul 1, 2008
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 18.7 years ago
Interventions
sitagliptin phosphatedrug
sitagliptin 100 mg tablets q.d. (once daily) for 7 days.
sitagliptin phosphatedrug
sitagliptin 200 mg tablets q.d. (once daily) for 7 days.
Comparator: Placebodrug
sitagliptin 100 mg \& 200 mg matching Placebo tablets q.d. (once daily) for 7 days.